118 related articles for article (PubMed ID: 23886164)
1. Predictive impact of common variations in DNA repair genes on clinical outcome of osteosarcoma.
Bai SB; Chen HX; Bao YX; Luo X; Zhong JJ
Asian Pac J Cancer Prev; 2013; 14(6):3677-80. PubMed ID: 23886164
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms in the NER pathway and clinical outcome of patients with bone malignant tumors.
Sun XH; Hou WG; Zhao HX; Zhao YL; Ma C; Liu Y
Asian Pac J Cancer Prev; 2013; 14(3):2049-52. PubMed ID: 23679317
[TBL] [Abstract][Full Text] [Related]
3. The association of XPG and MMS19L polymorphisms response to chemotherapy in osteosarcoma.
Zhao YL; Yang LB; Geng XL; Zhou QL; Qin H; Yang L; Dong YZ; Zhong JJ
Pak J Med Sci; 2013 Sep; 29(5):1225-9. PubMed ID: 24353725
[TBL] [Abstract][Full Text] [Related]
4. Glutathione S-transferase P1 and DNA polymorphisms influence response to chemotherapy and prognosis of bone tumors.
Yang LM; Li XH; Bao CF
Asian Pac J Cancer Prev; 2012; 13(11):5883-6. PubMed ID: 23317281
[TBL] [Abstract][Full Text] [Related]
5. Genetic polymorphisms in nucleotide excision repair pathway influences response to chemotherapy and overall survival in osteosarcoma.
Sun Y; Wu Y; Li W; Kong Z; Zou X
Int J Clin Exp Pathol; 2015; 8(7):7905-12. PubMed ID: 26339355
[TBL] [Abstract][Full Text] [Related]
6. Effect of variation of ABCB1 and ABCC3 genotypes on the survival of bone tumor cases after chemotherapy.
Yang J; Wang ZG; Cai HQ; Li YC; Xu YL
Asian Pac J Cancer Prev; 2013; 14(8):4595-8. PubMed ID: 24083708
[TBL] [Abstract][Full Text] [Related]
7. Investigation on the DNA repaired gene polymorphisms and response to chemotherapy and overall survival of osteosarcoma.
Ji WP; He NB
Int J Clin Exp Pathol; 2015; 8(1):894-9. PubMed ID: 25755792
[TBL] [Abstract][Full Text] [Related]
8. Influence of XPC, XPD, XPF, and XPG gene polymorphisms on the risk and the outcome of acute myeloid leukemia in a Romanian population.
Bănescu C; Iancu M; Trifa AP; Dobreanu M; Moldovan VG; Duicu C; Tripon F; Crauciuc A; Skypnyk C; Bogliș A; Lazar E
Tumour Biol; 2016 Jul; 37(7):9357-66. PubMed ID: 26779634
[TBL] [Abstract][Full Text] [Related]
9. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
[TBL] [Abstract][Full Text] [Related]
10. Association of four ERCC1 and ERCC2 SNPs with survival of bone tumour patients.
Hao T; Feng W; Zhang J; Sun YJ; Wang G
Asian Pac J Cancer Prev; 2012; 13(8):3821-4. PubMed ID: 23098477
[TBL] [Abstract][Full Text] [Related]
11. DNA repair genes XPC, XPG polymorphisms: relation to the risk of colorectal carcinoma and therapeutic outcome with Oxaliplatin-based adjuvant chemotherapy.
Liu D; Wu HZ; Zhang YN; Kang H; Sun MJ; Wang EH; Yang XL; Lian MQ; Yu ZJ; Zhao L; Olopade OI; Wei MJ
Mol Carcinog; 2012 Oct; 51 Suppl 1():E83-93. PubMed ID: 22213216
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of DNA repair-related genes with susceptibility and prognosis of prostate cancer.
Zhang XJ; Liu P; Zhu F
Genet Mol Res; 2014 Jan; 13(2):4419-24. PubMed ID: 24615090
[TBL] [Abstract][Full Text] [Related]
13. Investigation of ERCC1 and ERCC2 gene polymorphisms and response to chemotherapy and overall survival in osteosarcoma.
Zhang Q; Lv LY; Li BJ; Zhang J; Wei F
Genet Mol Res; 2015 Sep; 14(3):11235-41. PubMed ID: 26400354
[TBL] [Abstract][Full Text] [Related]
14. Major efficacy of trabectedin in 2 metastatic osteosarcoma patients with wild-type Asp1104 ERCC5 tumor status.
Gastaud L; Saâda-Bouzid E; Le Morvan V; Pourquier P; Ianessi A; Thariat J; Italiano A; Thyss A
Onkologie; 2013; 36(11):670-3. PubMed ID: 24192772
[TBL] [Abstract][Full Text] [Related]
15. Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients.
Caronia D; Patiño-García A; Milne RL; Zalacain-Díez M; Pita G; Alonso MR; Moreno LT; Sierrasesumaga-Ariznabarreta L; Benítez J; González-Neira A
Pharmacogenomics J; 2009 Oct; 9(5):347-53. PubMed ID: 19434073
[TBL] [Abstract][Full Text] [Related]
16. Predictive impact of genetic polymorphisms in DNA repair genes on susceptibility and therapeutic outcomes to colorectal cancer patients.
Sun K; Gong A; Liang P
Tumour Biol; 2015 Mar; 36(3):1549-59. PubMed ID: 25355595
[TBL] [Abstract][Full Text] [Related]
17. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
[TBL] [Abstract][Full Text] [Related]
18. XPG rs2296147 T>C polymorphism predicted clinical outcome in colorectal cancer.
Wang F; Zhang SD; Xu HM; Zhu JH; Hua RX; Xue WQ; Li XZ; Wang TM; He J; Jia WH
Oncotarget; 2016 Mar; 7(10):11724-32. PubMed ID: 26887052
[TBL] [Abstract][Full Text] [Related]
19. Predictive potential of ABCB1, ABCC3, and GSTP1 gene polymorphisms on osteosarcoma survival after chemotherapy.
Liu S; Yi Z; Ling M; Shi J; Qiu Y; Yang S
Tumour Biol; 2014 Oct; 35(10):9897-904. PubMed ID: 24996541
[TBL] [Abstract][Full Text] [Related]
20. The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients.
Obiedat H; Alrabadi N; Sultan E; Al Shatti M; Zihlif M
BMC Med Genet; 2018 Jul; 19(1):112. PubMed ID: 29980176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]